Cyproterone acetate in treatment of precocious puberty.
Twenty-nine children (23 girls, 6 boys) with precocious puberty were treated with cyproterone acetate for various periods of time ranging from 6 months to 3 years 4 months. They received an oral dose ranging from 70-150 mg/m2 per day, or an intramuscular depot injection once a fortnight or once a month at a dose ranging from 107-230 mg/m2. Both forms of therapy were found to suppress the signs of sexual maturation, but the oral form proved to be superior. Only the younger patients with a bone age under 11 years showed a beneficial effect upon linear growth and bone maturation. No side effects were noted, but additional advantageous effects upon behaviour and sociability were. It is concluded that at present cyproterone acetate by mouth is the drug of choice in the treatment of precocious puberty. The treatment should be initiated as early as possible to attain maximum benefit.
D000284:Administration, Oral; D000293:Adolescent; D001519:Behavior / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003534:Cyproterone / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006128:Growth / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011629:Puberty, Precocious / Q000188:drug therapy*; D012885:Skinfold Thickness
D003534:Cyproterone